Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price traded up 6.2% during trading on Thursday . The stock traded as high as $4.31 and last traded at $4.31, with a volume of 58,969 shares trading hands. The stock had previously closed at $4.06.

Several equities analysts have commented on the company. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. FBR & Co reiterated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Friday, August 26th. Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research report on Sunday, August 21st. Finally, Maxim Group set a $6.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 18th.

The stock has a 50-day moving average price of $3.34 and a 200 day moving average price of $2.85. The company’s market capitalization is $144.91 million.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Analysts predict that Abeona Therapeutics Inc. will post ($0.71) EPS for the current fiscal year.

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.